Ligand-targeted therapeutics in anticancer therapy

  title={Ligand-targeted therapeutics in anticancer therapy},
  author={Theresa M. Allen},
  journal={Nature Reviews Cancer},
  • T. Allen
  • Published 1 October 2002
  • Biology, Medicine
  • Nature Reviews Cancer
Cytotoxic chemotherapy or radiotherapy of cancer is limited by serious, sometimes life-threatening, side effects that arise from toxicities to sensitive normal cells because the therapies are not selective for malignant cells. So how can selectivity be improved? One strategy is to couple the therapeutics to antibodies or other ligands that recognize tumour-associated antigens. This increases the exposure of the malignant cells, and reduces the exposure of normal cells, to the ligand-targeted… 

Principles in the design of ligand-targeted cancer therapeutics and imaging agents

This Review describes the major principles in the design of ligand-targeted drugs and provides an overview of lig and–drug conjugates and ligand–imaging-agent conjugate that are currently in development.

Biologics in Targeted Cancer Therapy

This chapter presents an overview with preclinical and clinical data for different agents which were turned into targeted therapeutics and their conjugation/fusion to tumor-specific antibodies.

Arming antibodies for cancer therapy.

  • P. Polakis
  • Biology, Medicine
    Current opinion in pharmacology
  • 2005

Role of antibodies in cancer targeting

  • H. Attarwala
  • Biology
    Journal of natural science, biology, and medicine
  • 2010
In this review, the role of antibodies for cancer diagnosis, chemoprevention, and chemotherapy will be discussed with an emphasis on recent advances in antibody engineering.

Monoclonal antibodies in therapy of solid tumors.

Gemcitabine Peptide-Based Conjugates and Their Application in Targeted Tumor Therapy

This work summarizes recently published gemcitabine peptide-based conjugates and their efficacy in anticancer therapy and focuses on the direct targeting of chemotherapeutics to cancer cells using the drug-peptide conjugacy.

Antibody targeted drugs as cancer therapeutics

Recent preclinical and clinical data for antibody–drug conjugates and fusion proteins with a special focus on drug components that exert their antitumour effects through normal biological processes are discussed.

Ligand-Mediated Targeting: An Update

  • T. Allen
  • Biology, Medicine
    2004 International Conference on MEMS, NANO and Smart Systems (ICMENS'04)
  • 2004
Many nanoparticle delivery systems for anticancer drugs have also entered the clinic and have been shown to have improved anticancer effects over conventional chemotherapeutic drugs due to their ability to improve the pharmacokinetics and pharmacodynamics of their associated drugs.



Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs.

Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors.

There are many potential barriers to the effective delivery of a drug in its active form to solid tumors. Most small-molecule chemotherapeutic agents have a large volume of distribution on i.v.

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

This review focuses on the activities of several mAb-enzyme/prodrug combinations, with an emphasis on those that have provided mechanistic insight, clinical activity, novel protein constructs, and the potential for reduced immunogenicity.

Improving the efficacy of antibody-based cancer therapies

A quarter of a century after their advent, monoclonal antibodies have become the most rapidly expanding class of pharmaceuticals for treating a wide variety of human diseases, including cancer, and many innovative approaches stand poised to improve the efficacy of antibody-based therapies.

Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates.

  • P. WallaceP. Senter
  • Biology, Chemistry
    Methods and findings in experimental and clinical pharmacology
  • 1994

Effective targeted cytotoxicity of neuroblastoma cells.

This study demonstrates creation of a novel fusion toxin with effective GD(2)-targeted cellular toxicity and further investigation of this fusion toxin as a therapeutic agent in the management of neuroblastoma is warranted.

Liposome targeting to tumors using vitamin and growth factor receptors.

Folate-targeted liposomes for drug delivery

Folate, as a targeting ligand, offers unique advantages over immunoliposomes, i.e., easy liposomal incorporation, low cost, high receptor affinity and tumor specificity, extended stability, and potential lack of immunogenicity.

Therapeutic opportunities for targeted liposomal drug delivery

In vitro and in vivo targeting of immunoliposomal doxorubicin to human B-cell lymphoma.

It is inferred that targeted anti-CD19 liposomes containing the anticancer drug DXR may be selectively cytotoxic for B cells and may be useful in the selective elimination of circulating malignant B cells in vivo.